HOME >> MEDICINE >> NEWS
Is complementary medicine cost effective?

More doubts are cast over the cost effectiveness of complementary medicine in this week's BMJ.

The cost-effectiveness of using complementary treatments in the United Kingdom has been the subject of much speculation and controversy.

For instance, a report commissioned by the Prince of Wales last week said that complementary therapies should be given a greater role in the NHS, while others believe that more studies are needed before they are made widely available.

As an example of how poor the evidence is, researchers carried out a systematic review of cost effectiveness analyses of complementary treatments. They found only five studies done in the UK before April 2005, one of acupuncture for headache and four of spinal manipulation for back pain.

They conclude that these treatments represent an additional cost to usual care with questionable clinical benefit.

In an accompanying editorial, two senior doctors and general practice researchers suggest that complementary medicine should be considered for inclusion in national clinical guidelines despite limited evidence of cost effectiveness.

They believe that the integration into the NHS of specific complementary therapies for chronic conditions would be beneficial to patients, but that each therapy needs to be considered on its merits, including cost-effectiveness.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-20-7383-6529
BMJ-British Medical Journal
13-Oct-2005


Page: 1

Related medicine news :

1. Should NICE evaluate complementary medicine?
2. Cancer patients hide their use of complementary and alternative treatments from their doctors
3. Pediatric use of complementary and alternative medicine
4. Surgery by satellite -- New possibilities at medicines cutting edge
5. New drug development facility helps move medicines to market
6. To get blood pressure under control, combination of medicines may be best
7. Italian doctors get their information on medicines from drug company sales reps
8. Nanomedicine opens the way for nerve cell regeneration
9. Conference to focus on transfer of knowledge from research to practice in emergency medicine
10. SNMs 54th Annual Meeting speakers address state of molecular imaging/nuclear medicine technologies
11. US Senate introduces bill to train more preventive medicine doctors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: complementary medicine cost effective

(Date:8/20/2014)... 20, 2014 Hope For The Warriors® ... Celebration to be hosted in Washington, DC on Thursday, ... This signature event honors the courage of our wounded ... fallen. Proceeds from the Got Heart, Give Hope® Celebration ... dedicated to restoring a sense of self, restoring the ...
(Date:8/20/2014)... WA (PRWEB) August 20, 2014 “Have you ... an auto accident and personal injury lawyer serving the greater ... that incident? If so, then keep reading . , ... that individuals injured in an auto accident can use to ... Jones explains that a personal injury insurance claim will allow ...
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:8/20/2014)... Burlingame, CA (PRWEB) August 20, 2014 ... publishers to speech-enable their websites and create a new ... users to consume content by listening to a narration ... in multiple reader genders and languages. Users can ... work, check social networks, while consuming content. ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 Over ... the Global Bureau of Disease, low back pain is the ... the most common reasons for missed work. Americans spend at ... this pain. , Most cases of back pain are not ... mechanical (non-organic) origin. , For example, Pete, a busy accountant, ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2
(Date:8/19/2014)... British Columbia and MENLO PARK, Calif. ... (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol ... trial had been filed with the U.S. Food and Drug ... 50mg/m 2 has been opened at three clinical trial ... company also confirmed that gross proceeds of US$2.9 million have ...
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Israel , Aug. 19, 2014 Immune ... Stockholm : "IMNP"), a biotechnology company, today announced ... its common stock on the NASDAQ Capital Market has been ... NASDAQ OMX Group. IMMUNE,s common stock is expected to begin ... trading on August 21, 2014 under the symbol IMNP. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
Cached News: